SUPPORT FOR NATIONAL PRIMATE RESEARCH CENTER Memorial Sloan-Kettering Cancer Center (MSKCC) is a free-standing NCI-designated Comprehensive Cancer Research Center dedicated to research and training, with the mission of changing and setting the standards of treatment, prevention and control of cancer through inpatient and outpatient care. MSKCC's research programs are grouped into three categories: Basic Research (Regulation of Cell Behavior, Developmental and Stem Cell Biology, Genomic Integrity, and Molecular Structure); Bridge Research (Cancer Biology and Experimental Pathology, Experimental Therapeutics, Immunology and Transplantation, and Imaging and Radiation Sciences); and Patient-Oriented Research (Clinical Research and Survivorship, Outcomes and Risk). The programs are designed to optimize the use of a large patient population and an extensive, multi-disciplinary staff of clinical and laboratory-based Investigators and to encourage the application of discoveries in the basic sciences in a way that advances the prevention, detection, diagnosis, and treatment of many forms of cancer. Scientific work in the 10 research programs depends on services provided by 34 core facilities. We are requesting funding from the Cancer Center Support Grant (CCSG) for 21 of these core facilities. During the next five years, MSKCC will continue to enlarge its clinical and research facilities and its research and training programs in key research areas. Support is requested to provide developmental funding for the laboratories of new Investigators recruited in research areas aligned with the Center's strategic vision, to support cross-disciplinary pilot projects in population science research, and to support the core facilities.

Public Health Relevance

Memorial Sloan-Kettering Cancer Center (MSKCC) is a free-standing institution dedicated to the control of cancer through inpatient and outpatient care, clinical and research training programs, and a broad spectrum of research activities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA008748-50S6
Application #
9340624
Study Section
Subcommittee A - Cancer Centers (NCI-A)
Program Officer
Shafik, Hasnaa
Project Start
1997-01-20
Project End
2018-12-31
Budget Start
2016-01-01
Budget End
2016-12-31
Support Year
50
Fiscal Year
2016
Total Cost
$999,291
Indirect Cost
$416,274
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Pietzak, Eugene J; Assel, Melissa; Becerra, Maria F et al. (2018) Histologic and Oncologic Outcomes Following Liver Mass Resection With Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Germ Cell Tumor. Urology 118:114-118
Hicks, Angel Mier; DeRosa, Antonio; Raj, Micheal et al. (2018) Visceral Thromboses in Pancreas Adenocarcinoma: Systematic Review. Clin Colorectal Cancer 17:e207-e216
Phillips, Gregory S; Freites-Martinez, Azael; Hsu, Meier et al. (2018) Inflammatory dermatoses, infections, and drug eruptions are the most common skin conditions in hospitalized cancer patients. J Am Acad Dermatol 78:1102-1109
Chang, Matthew T; Penson, Alexander; Desai, Neil B et al. (2018) Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis. Clin Cancer Res 24:1965-1973
Trevino, Kelly M; Litz, Brett; Papa, Anthony et al. (2018) Bereavement Challenges and Their Relationship to Physical and Psychological Adjustment to Loss. J Palliat Med 21:479-488
Hayes, Richard B; Ahn, Jiyoung; Fan, Xiaozhou et al. (2018) Association of Oral Microbiome With Risk for Incident Head and Neck Squamous Cell Cancer. JAMA Oncol 4:358-365
Chen, Nan; Li, Xiaoyu; Chintala, Navin K et al. (2018) Driving CARs on the uneven road of antigen heterogeneity in solid tumors. Curr Opin Immunol 51:103-110
Juric, Dejan; Rodon, Jordi; Tabernero, Josep et al. (2018) Phosphatidylinositol 3-Kinase ?-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. J Clin Oncol 36:1291-1299
Kim, Kwanghee; Watson, Philip A; Lebdai, Souhil et al. (2018) Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts. Clin Cancer Res 24:2408-2416
McKay, Rana R; Montgomery, Bruce; Xie, Wanling et al. (2018) Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade. Prostate Cancer Prostatic Dis 21:364-372

Showing the most recent 10 out of 8799 publications